首页> 外文期刊>AIMS Genetics >Cardiac biomarkers in dialysis
【24h】

Cardiac biomarkers in dialysis

机译:透析中的心脏生物标志物

获取原文
           

摘要

Cardiovascular disease is the major cause of death, accounting for approximately 40 percent of all-cause mortality in patients receiving either hemodialysis or peritoneal dialysis. Cardiovascular risk stratification is an important aspect of managing dialysis patients as it enables early identification of high-risk patients, so therapeutic interventions can be optimized to lower cardiovascular morbidity and mortality. Biomarkers can detect early stages of cardiac injury so timely intervention can be provided. The B-type natriuretic peptides (Brain Natriuretic peptide [BNP] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and troponins have been shown to predict mortality in dialysis patients. Suppression of tumorigenicity 2 (ST2) and galectin-3 are new emerging biomarkers in the field of heart failure in both the general and dialysis populations. This article aims to discuss the current evidence regarding cardiac biomarker use to diagnose myocardial injury and monitor the risk of major adverse cardiovascular events in patients undergoing dialysis.
机译:心血管疾病是主要的死亡原因,在接受血液透析或腹膜透析的患者中,约占全部原因死亡率的40%。心血管风险分层是管理透析患者的重要方面,因为它可以及早识别高危患者,因此可以优化治疗干预措施,以降低心血管疾病的发病率和死亡率。生物标记物可以检测出心脏损伤的早期阶段,因此可以提供及时的干预。 B型利钠肽(脑利钠肽[BNP]和N端pro-B型利钠肽[NT-proBNP])和肌钙蛋白可预测透析患者的死亡率。在一般人群和透析人群中,抑制致瘤性2(ST2)和半乳凝素3是心力衰竭领域中新兴的生物标志物。本文旨在讨论有关心脏生物标记物用于诊断心肌损伤并监测接受透析的患者发生重大不良心血管事件的风险的当前证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号